Hepatitis/MASH

Strategies for rescuing PTPRD function in diseased livers could provide potential therapeutic options, according to the study authors.

The prevalence of hepatitis D virus (HDV) antibody positivity was about 0.24% in patients with chronic hepatitis B virus (HBV).

Among the 9 surface disinfectants studied, only 2 demonstrated a reduction in viral titer below the limit of detection.

Currently, BEAM-302 is undergoing a phase 1/2 clinical trial to evaluate its efficacy in patients with alpha-1 antitrypsin deficiency (AATD) who have lung disease and liver disease.

The hepatitis B core-related antigen (HBcrAg) rapid diagnostic test was more timely and showed a stronger sensitivity and specificity compared with other testing methods.

Patients with chronic hepatitis B (CHB) who received the Hecolin hepatitis E virus (HEV) 3-dose regimen had a somewhat low incidence of local and systemic adverse events.

DC646 had a strong safety profile, targeted intestinal FXR, and disrupted FXR-co-activator interactions in metabolic dysfunction-associated steatohepatitis (MASH).

Untargeted lipidomics identified a glycerophospholipid and sphingolipid signature that differentiated severe alcohol-related hepatitis (sAH) from decompensated cirrhosis (DC).

A team of clinical and academic experts from the Association of Anaesthetists produced a consensus statement outlining the key components to minimizing the impact of harmful alcohol intake in the surgical population.

Patients with metabolic dysfunction-associated steatohepatitis (MASH) receiving 300 mg of vitamin E daily presented improved steatosis, lobular inflammation, and fibrosis stages.

Although tenofovir amibufenamide and tenofovir disoproxil fumarate (TDF) had similar effects, the former resulted in better renal safety and did not impact lipid levels.

The long-term durability of response will be evaluated in the B-Sure trial (NCT04954859), which will enroll patients with hepatitis B virus (HBV) from B-Together (NCT04676724).

Although larsucosterol did not show statistical significance, it showed clinically meaningful trends in 90-day mortality in patients with severe alcohol-associated hepatitis.

This surgery can be significant in reducing the long-term risk of adverse outcomes and decompensation in cirrhosis related to metabolic dysfunction-associated steatohepatitis (MASH).

Efruxifermin is undergoing 3 phase 3 clinical trials to evaluate its safety, efficacy, and tolerability in metabolic dysfunction-associated steatohepatitis (MASH).

The model also predicted prevalent cases of decompensated cirrhosis would more than triple, incident liver cancer cases would nearly double, and transplant almost quadruple.

The authors note that this may cause disruptions in the metabolic stability of lipid processing and storage, impacting the liver and accelerating damaging adaptative responses.

The study shows benefits when Hecolin (HEV 239; Xiamen Innovax Biotech Co Ltd) is administered in 2 doses, rather than the typical 3-dose regimen.

Despite the reductions in hepatitis B surface antigen (HBsAg), grade 3 and 4 adverse events were not uncommon.

Severe alcohol-associated hepatitis has limited effective pharmacological therapies, emphasizing the need for treatment options.

The treatments are currently undergoing evaluation in the SOLSTICE trial (NCT05461170).

Survodutide is a glucagon/glucagon-like peptide-1 (GLP-1) receptor dual agonist that activates the glucagon and GLP-1 receptors to better control metabolic function.

Positive trial results laid the groundwork for the designation.

A lack of widespread hepatitis B screenings compound with the issue of inaccurate test results, which can complicate treatment with intravenous immunoglobulin.

Study finds traces of “epigenetic scars” on the immune cells of patients who recovered from chronic hepatitis C infection.

Treatment often involves a complex daily routine of reconstitution and subcutaneous injection, along with strict storage requirements.

In the 2 mg bulevirtide (Gilead Sciences) group, 44% of individuals achieved HDV RNA that was undetectable compared with 70% in the 10 mg group.

Investigators found improvements over the placebo in metabolic dysfunction-associated steatohepatitis without worsening fibrosis across 3 dosing groups.

The test can be performed in settings that operate under the Clinical Laboratory Improvement Amendments waiver, including community pharmacies.

Lindsey P. Sheehan, PharmD, MPA, MBA, discusses ongoing challenges of diagnosing and treating hepatitis C, emphasizing its increased incidence among younger populations and ongoing low rates of diagnosis.